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Highlights 
• CYP2D6 genotype-based phenotype estimation is of particular importance to 
personalized medication strategy. 
• The non-sequencing genotyping platform identified the most frequent CYP2D6 allelic 
variants (in 67% of the donors). 
• The gain-of-function mutation (-1584C>G) could explain the underestimation of 
CYP2D6 genotype-based prediction. 
• Some rare loss-of-function mutations that were not captured, could result in 
overestimation of CYP2D6 activity prediction. 
• CYP2D6 phenotype overestimation may also come from external factors modifying 
CYP2D6 activity or altering hepatic function. 
• A comprehensive genotyping and consideration of phenoconversion can improve the 
genotype-based CYP2D6 phenotype prediction. 
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Abstract 
Genetic polymorphism of cytochrome P450s results in clinically significant modifications in 
patients’ drug metabolizing capacities. CYP2D6 has a crucial role in the elimination of 
several clinically important drugs (antiarrhythmics, beta-adrenergic blockers, 
psychopharmacons and analgesics); however, the prediction of the phenotypic appearance of 
CYP2D6 is a challenge. Since single nucleotide polymorphisms and gene copy number 
variations (gene deletion and multiplication) frequently occur in CYP2D6 gene, CYP2D6 
activity particularly depends on the genetic factors.  
Microsomal CYP2D6 activities (dextromethorphan O-demethylation) and CYP2D6 genotypes 
for the most frequent allelic variants (CYP2D6*3, *4, *5, *6, *10, *41 and duplication) were 
determined in 128 human liver samples derived from Hungarian organ donors. Substantial 
inter-individual variations were observed in CYP2D6 metabolic activities that were 
successfully predicted from the CYP2D6 genotypes in 67% of the donors. The 
underestimation of CYP2D6 phenotypes in 12.5% of the donors was assumed to be originated 
from the overlapping ranges of CYP2D6 activity among similar diplotypes or from the 
presence of -1584C>G in the promoter region evoking increased transcription of the 
wild-type CYP2D6 allele. In an appreciable number of donors (20.3%), the genotype-based 
CYP2D6 phenotype prediction was overestimated because of the rare CYP2D6 allelic variants 
which were not included in our genotyping platform or some external factors that could alter 
CYP2D6 activity (medication with CYP2D6 substrate/inhibitor) and hepatic function 
(Augmentin therapy, chronic alcohol consumption). 
In conclusion, CYP2D6 genotyping for the most frequent allelic variants was able to reliably 
predict CYP2D6 phenotypes in most donors; however, the external factors modifying the 
phenotypic appearance of CYP2D6 had to be taken into account. Personalized medication 
strategy should include monitoring of CYP2D6 genotype in a more comprehensive manner 
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and should take external factors into consideration for an appropriate prediction of CYP2D6 
metabolizing capacity.  
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1. Introduction 
Most drugs show inter-individual differences in their responses and efficacy due to the 
substantial variability of the capacity of drug metabolizing enzymes between individuals. The 
primary drug metabolizing enzymes belong to the cytochrome P450 (CYP) superfamily, 
which are responsible for the metabolism of more than 90 percent of the drugs on the market. 
In mammalian species, CYP enzymes are present in most tissues (e.g. gut wall, kidney, brain, 
lung); however, they are mainly expressed in the liver. Most of them are highly polymorphic 
resulting in clinically significant modifications in drug metabolizing capacities. The major 
genetic polymorphisms influencing drug metabolizing activity are related to the metabolism 
by CYP2D6. Although CYP2D6 presents only a small proportion of hepatic CYP enzymes 
(2%), it is one of the most important drug metabolizing enzymes, catalysing the metabolism 
of approximately 25% of the drugs on the market. CYP2D6 is involved in the 
biotransformation of numerous clinically used drugs, such as beta-blockers (metoprolol, 
bufuralol, propranolol), opioids (codeine, tramadol), antidepressants (amitriptyline, 
imipramine, fluoxetine, mianserin, venlafaxine), antipsychotics (aripiprazole, haloperidol, 
olanzapine, risperidone), antitussives (dextromethorphan) and anticancer drugs (tamoxifen) 
[1]. 
The CYP2D6 gene is located on chromosome 22q13.1 nearby two homologous, 
non-functional pseudogenes, CYP2D7P and CYP2D8P [2]. CYP2D6 gene is highly 
polymorphic; hitherto more than one hundred allelic variants were identified, a number of 
them containing mutations that have clinically relevant impact 
(http://www.cypalleles.ki.se/cyp2d6.htm) [34]. Both single nucleotide polymorphisms (SNP) 
and gene copy number variations (CNV) (such as gene deletion and 
duplication/multiplication) frequently occur. Among the allelic variants, there are fully 
functional alleles (e.g. *1, *2), alleles with reduced function (e.g. *9, *10, *41) and null (non-
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functional) alleles (e.g. *3, *4, *5, *6). Duplication of the functional allele leads to increased 
gene expression and enzyme activity [3, 4]. Due to the wide range of CYP2D6 enzyme 
activity within the population, the patients can be divided into four metabolizer groups: poor 
(PM), intermediate (IM), extensive (EM) and ultra-rapid metabolizers (UM) [5]. Since 
CYP2D6 gene expression is not inducible by xenobiotics, genetic factors are thought to play a 
substantial role in the phenotypic appearance of CYP2D6. 
Typically, subjects considered to be PMs carry two non-functional alleles which do not 
encode a functional protein product; thus, they do not display detectable enzyme activity. 
Several studies established clinical risks in the case of PM patients treated with CYP2D6 
substrate drugs [5-7]. The most frequent non-functional allelic variant is CYP2D6*4 in 
Caucasians (European white population) with an allele frequency of 18-23% [8]. CYP2D6*3 
and *6 allelic variants, which occur at allele frequency of about 1% in Caucasians, contain 
one nucleotide deletion causing frame-shift mutation and the lack of functional CYP2D6 
protein. CYP2D6*5, which occurs in 2-5% of Caucasians, means the deletion of the entire 
gene and the lack of CYP2D6 enzyme expression [9]. The alleles CYP2D6*10 and *41 give 
rise to significantly decreased enzyme activity. However, the allele frequency of CYP2D6*10 
is 1-2% in Caucasians, this allele variant is typical in the Asian population with an allele 
frequency of 33-43% [10]. CYP2D6*10 has a 100C>T SNP leading to the instability of the 
enzyme protein [11]. CYP2D6*41 contains an intronic 2988G>A SNP causing increased 
levels of a non-functional splice variant and accordingly lower CYP2D6 metabolic activity 
[12]. CYP2D6*41 frequently occurs in Caucasians (allele frequency: 7-10%) [13]. UM 
phenotype has also clinical relevance, since high enzyme activity can be responsible for 
adverse drug effects or for therapeutic failure depending on the used drug. Primarily, 
duplication or multiplication of the functional CYP2D6 gene accounts for UM phenotype; 
however, copy number increase does not explain all cases of UMs [14]. 
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Up to now, several in vivo and in vitro studies were implemented to investigate an applicable 
formula with which certain CYP2D6 genotype could be translated to the corresponding 
phenotype. For example, Gaedigk et al. [15] introduced an activity score system, which 
assigns a number for each allelic variant depending on the functionality of the allele. 
Although more investigations were achieved at in vivo conditions to evaluate the effect of 
CYP2D6 polymorphism directly on the enzyme activity, human derived systems, such as 
human liver microsomes, are recommended to be used. Incubation of the microsomes with 
CYP-specific substrates provides direct information about the specific CYP enzyme activity. 
Due to the clinical significance of the medications metabolized by CYP2D6, it would be 
important to obtain accurate estimation of CYP2D6 activity based on a fast and simple 
genotyping method. The aim of the present work was to investigate the accuracy of CYP2D6 
phenotype prediction from genotype and the reliability of CYP2D6 genotype interpretation. 
Human liver microsomes were used to evaluate CYP2D6 metabolic activity, and the samples 
were genotyped for the most frequent allelic variants in the Caucasian population.  
 
 
 
2. Materials and methods 
2.1 Human liver microsomes 
Human liver tissues (N=128) were obtained from organ transplant donors at the Department 
of Transplantation and Surgery, Semmelweis University (Budapest, Hungary). Permission of 
the Hungarian Committee of Science and Research Ethics was obtained to use human tissues. 
Clinical histories of the donors are shown in Table 1. Human livers were perfused with 
Euro-Collin’s solution (Fresenius AG, Bad Homburg vdH, Germany) and excised. The tissues 
were homogenized in 0.1 M Tris-HCl buffer (pH 7.4) containing 1 mM EDTA and 154 mM 
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KCl. Microsomes were prepared by differential centrifugation as described by van der 
Hoeven and Coon [16]. All procedures of preparation were performed at 4°C. Microsomal 
protein content was determined by the method of Lowry et al. [17] with bovine serum 
albumin as the standard. 
2.2 CYP2D6 enzyme assay 
Published method was followed to determine dextromethorphan O-demethylation selective 
for CYP2D6 enzyme [18]. The incubation mixture contained NADPH-generating system  
(1 mM NADPH, 10 mM glucose 6-phosphate, 5 mM MgCl2 and 2 units/ml glucose 
6-phosphate dehydrogenase), human liver microsomes (0.8 mg/ml) and the CYP2D6 selective 
substrate, dextromethorphan (1 mM). After a 20-min incubation, the reaction was terminated 
by ice-cold methanol and the incubation mixture was centrifuged for 10 min at 10.000×g. The 
supernatant was analysed for the concentration of dextromethorphan and its metabolite 
dextrorphan by HPLC-UV using a LiChroSpher C18 column (125 x 4 mm, 5µm) (Merck, 
Darmstadt, Germany). The mobile phase consisted of 1 mM Na-perchlorate (pH 2.6) and 
acetonitrile (71:29 v/v). The rates of enzyme activity were linearly dependent upon the 
amount of microsomal protein added for the incubation period. CYP2D6 enzyme assay for 
each donor was performed in triplicate and median (min, max) was calculated. 
2.3 CYP2D6 genotyping 
Hydrolysis single nucleotide polymorphism (SNP) analysis for CYP2D6*3, CYP2D6*4, 
CYP2D6*6, CYP2D6*10 and CYP2D6*41 was performed by polymerase chain reaction 
(PCR) with TaqMan probes (Metabion, Planegg/Steinkirchen, Germany) using a CFX96 
real-time detection system (Bio-Rad Laboratories). Primers and probes (Table 2) were 
designed based on the reference SNP sequences in the National Center for Biotechnology 
Information reference assembly. Genomic DNA was isolated from human liver samples by 
Quick-DNA™ Universal Kit (Zymo Research, Irvine, CA). PCR was carried out with 30 ng 
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of genomic DNA by using Luminaris Color Probe qPCR Master Mix (Thermo Fisher 
Scientific, Waltham, MA). Allelic discrimination was based on the design of two TaqMan 
probes, specific for the wild type allele and the mutant allele labelled with different 
fluorescent tags (FAM, CalRed610 or HEX). The corresponding CYP2D6 genotypes were 
distinguished by plotting the relative fluorescent values for wild type and mutant alleles, 
hereby three allelic clusters were determined: homozygous wild type, homozygous mutant 
and heterozygous genotype. To confirm the results of CYP2D6 genotyping, a sequence 
analysis was also performed. One hundred nanograms of DNA were amplified by using the 
primers designed for the hydrolysis SNP analysis and the Luminaris Color Probe qPCR 
Master Mix. The PCR products were sequenced directly in an ABI PRISM 3100 Genetic 
Analyzer (Applied Biosystems, Foster City, CA) by the Sequencing Service of Biomi Ltd. 
(Gödöllő, Hungary). 
To access CYP2D6 gene copy number, TaqMan® Copy Number Assay (assay id: 
Hs00010001_cn) was purchased from Thermo Fisher Scientific (Waltham, MA). To 
distinguish duplication of CYP2D6*1 allele and CYP2D6*4 allele, a real-time PCR method 
was developed combining quantitative PCR and genotyping PCR with TaqMan probes. 
Human RNase P was applied as the reference gene using TaqMan® Copy Number Reference 
Assay (Thermo Fisher Scientific, Waltham, MA). CYP2D6*4 genotyping and RNase P 
reference assay were performed parallel, then relative copies of the wild type (CYP2D6*1) 
and CYP2D6*4 alleles were obtained based on the relative quantity of each alleles compared 
to a control sample carrying exactly one wild type allele and one CYP2D6*4 allele. 20 ng of 
genomic DNA was used in a finale volume of 20 µl reaction and the PCR conditions were as 
follows: 50 °C for 2 min, 95°C for 10 min, then 40 cycles of 95°C for 15 s and 55°C for 60 s. 
Each sample was run in triplicate. Relative quantification of copy numbers was performed 
using CFX Manager Software Version 3.1 (Bio-Rad Laboratories). 
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2.4 Data analysis 
Hepatic CYP2D6 activities were determined individually in each donor, the frequency 
distribution of the CYP2D6 activities were recorded for 128 donors, and four categories (low, 
intermediate, high, ultra-high) were distinguished for poor, intermediate, extensive and 
ultra-rapid metabolizers. Approximately 10-15% of the donors displaying low CYP2D6 
activity (<95-100 pmol/[mg protein*min]) were designated as poor metabolizers, whereas 
10-15% of the donors with ultra-high activities (>720 pmol/[mg protein*min]) were 
designated as ultra-rapid metabolizers. The donors displaying CYP2D6 activities between 100 
and 720 pmol/(mg protein*min) were considered to be intermediate and extensive 
metabolizers. The cutoff value between intermediate and extensive metabolizers was the 
median of CYP2D6 activities (290 pmol/[mg protein*min]). The donors’ CYP2D6 
phenotypes were also predicted from their CYP2D6 genotypes, and the accuracy of prediction 
was evaluated on the basis of the activity-based CYP2D6 categories. The donors carrying two 
loss-of-function or reduced-function alleles (*3, *4, *5, *6, *10, *41) were considered to be 
poor metabolizers, those with one functional (*1) and one non-functional alleles were 
designated as intermediate metabolizers, the subjects with two functional alleles 
(CYP2D6*1/*1) were extensive metabolizers, whereas the donors carrying duplicated or 
multiplicated functional alleles (CYP2D6*1x2 or CYP2D6*1xN) were ultra-rapid 
metabolizers. 
 
3. Results 
3.1 Hepatic CYP2D6 activities 
CYP2D6 metabolic activities were determined in hepatic microsomal fractions of 128 
Hungarian deceased donors. Dextromethorphan was used as a substrate selective for 
CYP2D6, and the formation of dextrorphan was quantified based on „per mg of microsomal 
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protein and per minute”. The frequency distribution of CYP2D6 activities in the Hungarian 
organ donors is shown on Figure 1. Inter-individual variations of CYP2D6 activities ranged 
from non-detectable to rather high values and the activity values did not show a Gaussian 
distribution. The cutoff values (CI=95%) between the categories of poor, intermediate, 
extensive and ultra-rapid metabolizers were 95-100, 290 and 720 pmol/(mg protein*min), 
respectively (see 2.4). 
The inter-individual variations of CYP2D6 activity were not influenced by the donors’ 
demographic parameters, such as sex or age (data not shown). In most cases, the death of the 
donors was caused by cerebral hemorrhage/hematoma (62/128) or accident (30/128); 
however, the incidence of stroke and tumour was much less (7/128 and 16/128, respectively). 
Comparing the groups of donors categorized according to the cause of death, we found no 
significant differences in CYP2D6 metabolic activities among the groups (data not shown). 
Chronic alcohol consumption was diagnosed at 11 donors as well as four and two of the 128 
subjects received CYP2D6-substrates/inhibitors (beta-adrenergic blockers, metoprolol, 
haloperidol) and Augmentin (amoxicillin and clavulanic acid), respectively. 
 
3.2 The donors’ CYP2D6 genotypes 
CYP2D6 genotype-based phenotype prediction was performed for each donor by determining 
the allelic variants most frequently occurring in Caucasian populations. In Hungarian organ 
donors, the most frequent non-functional allele was CYP2D6*4, whereas CYP2D6*3, *5 and 
*6 occurred only in 2, 2 and 7 of 128 donors, respectively (Table 3). Particularly, the 
prevalence of the reduced function CYP2D6*41 allele was 7.8%, whereas CYP2D6*10 allele 
had lower occurrence in our cohort (3.5%). Interestingly, the duplication/multiplication of the 
CYP2D6 gene in 128 donors was extremely frequent (19.9%), in contrast to the duplication 
frequencies previously reported in Caucasians (2-5%). Rideg et al. [19] have reported 
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CYP2D6 gene duplication with 1.8% frequency in Hungarian population (N=112), similarly 
to the findings in other European cohorts [8, 15, 20, 33]. Wild-type allele (CYP2D6*1) was 
identified when none of the allelic variants (CYP2D6*3, *4, *5, *6, *10, *41 or duplication) 
was detected. -1584C>G SNP contributing to increased expression of CYP2D6 gene (Dorado 
et al. [21], Llerena et al. [22]), was also assayed in donors who carried CYP2D6*1/*1 
genotype to find associations between the mutation in the promoter region of CYP2D6 gene 
and UM phenotype.  
Duplication of the non-functional alleles, including the highly frequent CYP2D6*4 allele can 
also occur; however, such arrangements do not increase CYP2D6 activity. Copy number 
determination by TaqMan Copy Number Assay (Thermo Fisher Scientific) gives insufficient 
information about the copy number of different allelic variants in case of a heterozygous 
CYP2D6*1/*4 individual, since this assay cannot distinguish the duplication of the wild-type 
alleles (*1x2/*4) and non-functional alleles (*1/*4x2). We developed a novel fast and simple 
method combining quantitative PCR and genotyping PCR with TaqMan probes (see 2.3), 
whereby allele-specific copy number determination was successfully implemented on donors 
who were heterozygous for CYP2D6*4 allele. 
3.3 Association between dextromethorphan O-demethylase activity and CYP2D6 genotype 
CYP2D6 phenotypes of the 128 organ donors were predicted from their CYP2D6 genotypes 
categorizing them as poor, intermediate, extensive and ultra-rapid metabolizers according to 
the presence or absence of allelic variants with altered functionality. CYP2D6 genotype 
groups with the corresponding metabolic activities are shown in Figure 2. All the donors who 
had no wild type allele (CYP2D6*1) showed low CYP2D6 activity; however, we did not find 
differences in dextromethorphan O-demethylation activity between the donors with two 
non-functional alleles and those with one non-functional (*3, *4, *5 or *6) and one allele 
associated with reduced CYP2D6 function (*10 or *41). The donors with only one wild type 
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allele were considered to be IMs; however, due to the reduced activity attributed to 
CYP2D6*10 or CYP2D6*41 alleles, we were unable to define a strict border-line between IM 
and EM phenotype groups. Duplication of non-functional alleles has no effect on CYP2D6 
activity, thus CYP2D6*1/*4x2 and CYP2D6*1/*4 genotypes were considered to be identical 
in respect of the CYP2D6 activity. Two CYP2D6 genotype groups were considered to be 
EMs: 1) donors carrying CYP2D6*1/*1 and 2) subjects with duplicated wild type allele and 
one non-functional allele or allele variant with decreased function. These EM individuals with 
two functional alleles occurred in 45% of the organ donors. Although only two functional 
alleles were identified, seven donors displayed UM phenotype (dextromethorphan 
O-demethylation >720 pmol/[mg protein*min]). Two individuals with CYP2D6*1/*1 
genotype had extremely high CYP2D6 activity (1242 and 1461 pmol/[mg protein*min]), 
which was attributed to the heterozygous (CG) and the homozygous (GG) genotypes at the 
position of -1584. On the other hand, we found several donors (12/128) carrying two wild 
type alleles (CYP2D6*1/*1) whose hepatic microsomes displayed significantly lower activity 
than it could be predicted from the corresponding CYP2D6 genotype. Among these 
individuals, the anamnesis of four of them indicated chronic alcohol consumption, two were 
under CYP2D6 substrate or inhibitor therapy (beta adrenergic blockers, haloperidol), and one 
subject received Augmentin. The combination of amoxicillin and clavulanic acid in 
Augmentin has been reported to evoke liver dysfunction including reduced CYP activities 
[23]. UM phenotype is primarily attributed to CYP2D6 gene duplication/multiplication; 
however, of 13 subjects with ultra-rapid CYP2D6 activity (>720 pmol/[mg protein*min]), we 
found only 4 donors who carried more than two functional alleles (CYP2D6*1/*1x2). 
In conclusion, of 128 organ donors, the CYP2D6 phenotypes of 86 were successfully 
predicted from the genotypes. This means that the accuracy of prediction was 67%. CYP2D6 
phenotypes of 16 individuals were underestimated, and the elevated CYP2D6 activities in 5 
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donors could be explained with -1584C>G SNP, resulting in increased transcription of 
CYP2D6*1 allele [21, 22]. In 26 subjects, the phenotype was overestimated. Several 
individuals had PM phenotype (dextromethorphan O-demethylation activity lower than 100 
pmol/[mg protein*min]), despite the presence of two or more wild type alleles. External 
factors, such as CYP2D6 substrate or inhibitor therapy, chronic alcohol consumption and 
Augmentin therapy were observed in 17 of the 128 donors, which resulted in overestimation 
of CYP2D6 activity. 
4. Discussion 
CYP2D6 has a crucial role in the metabolism of several clinically important drugs; thus, any 
changes in CYP2D6 activity influence the patient’s response to a drug primarily metabolized 
by CYP2D6. According to the present knowledge, the expression of CYP2D6 gene is not 
inducible by any known xenobiotics in contrast to other drug metabolizing CYP enzymes [24, 
25]. Since CYP2D6 gene is remarkably polymorphic, the main factor that determines the 
enzyme activity is thought to be the genetic variations. Personalized medication requires a 
reliable method to predict CYP2D6 activity from patients’ genotype for a long while. Due to 
the numerous allelic variants, it is a challenge to elaborate an applicable method for CYP2D6 
phenotype prediction. Human liver cellular and subcellular systems, such as hepatocytes and 
microsomes, seem to be a good platform to investigate CYP2D6 genotype-phenotype 
associations. In this study, CYP2D6 metabolic activities were determined in human liver 
microsomes derived from Hungarian organ donors using dextromethorphan selective for 
CYP2D6. The liver samples were CYP2D6-genotyped for the most frequent allelic variants 
occurring in Caucasian populations. The allele frequencies for CYP2D6*3, *4, *5, *6, *10 
and *41 were concordant with previously reported data except for the prevalence of gene 
duplications (Table 3) [9, 24], which was substantially higher (19.9%) than it was reported in 
Caucasian populations (2-5%). We were unable to correlate the elevated frequency of 
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CYP2D6 duplication to any available clinical information about the donors. An association 
between CYP2D6 duplication and the cause of donors’ death may be assumed. Interestingly, 
the outstanding frequency of duplication was unequivocally observed in donors died because 
of cerebral hemorrhage (26%) or accident (33%). It should be emphasized that the most 
frequent causes of death were cerebral hemorrhage and accident (92/128). Nevertheless, 
elevated frequency of duplication was not observed among donors died owing to stroke (6%) 
or tumour (9%). Regarding to the location of the hemorrhage, the cerebral hemorrhage was 
mostly diagnosed as subarachnoidal hemorrhage/hematoma. Unfortunately, in terms of donors 
who died in accident, we had limited information about the circumstances; most of them were 
involved in car, motor or bike accident, however, some suggestive facts, such as suicide, 
asphyxia and seizure, were also listed as causes of fatal injuries. 
CYP2D6 phenotype prediction was based on the determination of the most frequent allelic 
variants occurring in Caucasians. The donors with two non-functional alleles displayed low 
CYP2D6 metabolic activity; albeit in some cases the formation rate of the metabolite 
dextrorphan was in the activity range of IM. The donors with one allele associated with 
reduced activity (CYP2D6*10 or *41) and one non-functional allele (CYP2D6*3, *4, *5 or 
*6) appear to display some activities resulting in poor or intermediate metabolizer 
phenotypes. In agreement with the preceding interpretation by Hicks et al. [26] and Gaedigk 
[27], the range of metabolic activity among similar CYP2D6 diplotypes can cover even two 
phenotype categories. Therefore making distinction between the subjects carrying two 
non-functional alleles and those with one non-functional and one reduced-function alleles is 
unnecessary. Since both genotypes result in low CYP2D6 activities, the strategy of 
personalized medication for such patients should take the dose reduction of CYP2D6 
substrates into consideration.  
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The presence of one functional (CYP2D6*1) and one non-functional alleles is considered to 
be associated with IM phenotype, and the genotype-based prediction for donors’ phenotype 
was correct in most subjects (17/22). Although the microsomal CYP2D6 activities of three 
donors were in EM activity range despite one functional allele, each of them carried 
the -1584C>G SNP, which was reported to evoke increased CYP2D6 expression [21, 22]. 
The presence of one functional (CYP2D6*1) and one reduced-function (CYP2D6*10 or *41) 
alleles can also be predicted to be translated to IM phenotype; however, CYP2D6*1/*10 or 
CYP2D6*1/*41 genotypes resulted in slightly increased CYP2D6 activities, reassigning these 
donors to EM activity group. It could be explained by the reduced function of CYP2D6*10 
and *41 allele variants, which entails a broader range of CYP2D6 activity spanning IM and 
EM phenotype categories [26, 27]. 
CYP2D6*1/*1 genotype, predicted to lead to EM phenotype, was identified in 36 donors; 
however, only 20 displayed dextromethorphan O-demethylation activity in the EM activity 
range and 16 were out of this range. In two of the CYP2D6*1/*1 donors, exhibiting the 
highest CYP2D6 activities, C>G SNP was detected at the position of -1584 (one was 
homozygous G/G, the other was C/G heterozygous), reassigning them to UM category. 
Twelve individuals showed significantly lower activities than it would be predicted from the 
CYP2D6*1/*1 genotype. More than half of the donors with CYP2D6*1/*1x2 genotype were 
also demonstrated to belong to the PM, IM or EM activity-based categories, although these 
individuals had more than two copies of the wild type allele that would designate UM 
phenotype.  
CYP2D6 genotype-based phenotype prediction overestimated CYP2D6 activity of 26 donors 
which can be explained by 1) the non-sequencing genotype platform we applied or 2) by some 
external factors that can modify the enzyme activity. Our non-sequencing genotyping 
approaches focused on some key polymorphisms that frequently occur in Caucasian 
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populations; thus, some rare loss-of-function or reduced-function variants were not captured. 
The phenotype overestimation due to some external factors influencing CYP2D6 enzyme 
activity has also been indicated by several authors [28-30]. The impact of CYP2D6 substrates 
or inhibitors, such as beta adrenergic blockers or antipsychotics (haloperidol, risperidone, 
aripiprazole) on CYP2D6 activity is obvious. The anamnesis of some donors indicated 
chronic treatment with beta adrenergic blockers or haloperidol, thus, our results could confirm 
that the genotype-predicted UM and EM donors were simply converted into IMs or PMs by 
these substrates/inhibitors. Phenotype conversion can also be attributed to some aspecific 
agents, such as Augmentin treatment or chronic alcohol consumption. Augmentin is an 
antibiotic drug containing the combination of amoxycillin and clavulanic acid. The 
hepatotoxic effect of both Augmentin and alcohol has been well described [23, 31, 32]; 
however, their impact on CYP2D6 is hardly investigated. Our results suggested that 
Augmentin or chronic alcohol exposure of the donors might contribute to the reduction of 
CYP2D6 activity, leading to the inconsequence of the CYP2D6 genotype-based phenotype 
prediction. Because of the hepatotoxic exposure, eleven subjects were found to be PMs or 
IMs despite the presence of two or more CYP2D6*1 alleles. In addition, differences in 
CYP3A4 expression and activity among the donors could have a minor role in the observed 
disparities between genotype and phenotype, since at a milimolar substrate concentration, the 
contribution of CYP3A4 to the catalysis of dextromethorphan O-demethylation increases 
[33]. 
In conclusion, the phenotype prediction from CYP2D6 genotype was acceptable for 
67% of the donors (86/128). The CYP2D6 activity of some donors (12.5%) was found to be 
somewhat higher than it would be predicted from their CYP2D6 genotypes. The 
underestimation was assumed to be originated from 1) the overlapping ranges of CYP2D6 
activity among similar diplotypes or 2) the presence of C>G at the position of -1584 evoking 
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increased transcription of certain CYP2D6 alleles. Although the -1584C>G SNP may account 
for the underestimation of CYP2D6 phenotype for some donors, the association between 
the -1584G allele and increased CYP2D6 activity requires further investigation. In an 
appreciable number of donors (20.3%), the genotype-based CYP2D6 phenotype prediction 
was overestimated because of the rare CYP2D6 allelic variants which were not included in 
our genotyping platform or because of the possible external factors that could alter CYP2D6 
activity and hepatic function. These findings suggested that although CYP2D6 genotyping for 
the most frequent allelic variants successfully predicted the phenotype in more than two thirds 
of the donors, some external factors could modify the phenotypic appearance of CYP2D6. 
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Table 1. Demographic data of the human organ donors 
 Demographic data  
Donor number  128 
Age (year) median (min; max) 45 (13; 74) 
Gender Male/female 67/61 
Cause of death    
 
Cerebral hemorrhage/ 
hematoma  62 
  Subarachnoid hemorrhage 42 
  Subdural hemorrhage 5 
  Epidural hematoma 1 
  Intraventricular hemorrhage 5 
  Ruptured cerebral aneurysm 4 
  Unknown 5 
 Stroke   7 
  Ischemic stroke 6 
  Hemorrhagic stroke 1 
 Tumour   16 
 Accident   30 
  Car/motor/bike accident 12 
  Seizure induced cerebral injury 1 
  Suicide 4 
  Asphyxia 1 
  Unknown cerebral injury 12 
 Unknown   13 
Anamnesis   
 Alcohol consumption 11 
 
Medication with CYP2D6 
substrate/inhibitor 4 
  Medication with agent which cause potential liver dysfunction 2 
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Table 2. Sequences of PCR primers and probes for CYP2D6 genotyping 
 
FAM, CalRed610 fluorescent labelling; BHQ, black hole quencher 
 
 
 Primer Sequence Probe Sequence 
CYP2D6*3 Forward 5'-TGGCAAGGTCCTACGC-3' Wild FAM-CACAGGATGACCTGGGACC-BHQ1 
 Reverse 5'-TCCATCTCTGCCAGGAAG-3' Mutant CalRed610-CACGGATGACCTGGGACC-BHQ2 
CYP2D6*4 Forward 5'-CTTCGCCAACCACTCC-3' Wild FAM-CCCCAAGACGCCC-BHQ1 
 Reverse 5'-GATCACGTTGCTCACG-3' Mutant CalRed610-CCCCAGGACGCCC-BHQ2 
CYP2D6*6 Forward 5'-TCTCCGTGTCCACCTTG-3' Wild FAM-GCTGGAGCAGTGGGTGAC-BHQ1 
 Reverse 5'-GCGAAGGCGGCACA-3' Mutant CalRed610-GCTGGAGCAGGGGTGAC-BHQ2 
CYP2D6*10 Forward 5'-TGAGGCAGGTATGGGGCTA-3' Wild FAM-GCACGCTACCCACCAGGC-BHQ1 
 Reverse 5'-CAGGTTGCCCAGCCC-3'  Mutant CalRed610-GCACGCTACTCACCAGGC-BHQ2 
CYP2D6*41 Forward 5'-TGGCTGACCTGTTCTCTGC-3' Wild FAM-GCCGAGGGAGGAAGGGTACAG-BHQ1 
  Reverse 5'-CCTGGTCAAGCCTGTGCT-3'  Mutant CalRed610-GCCGAGGGAGAAAGGGTACAG-BHQ2 
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Table 3. CYP2D6 allele frequencies in Hungarian organ donors (n=128) and in Caucasian 
populations 
CYP2D6 
allele Number 
Allele frequency (%) 
Donors Caucasians# 
*3 2 0.8 2 
*4 56 21.9 20-25 
*5 2 0.8 2-4 
*6 7 2.7 1 
*10 9 3.5 1-2 
*41 20 7.8 7-10 
Duplication 51 19.9 2-5 
#Based on allele frequencies reported by Sachse et al. [9], Ingelman-Sundberg [24] and 
www.cypalleles.ki.se/cyp2d6.htm [34] 
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Figure legends 
Figure 1. Frequency distribution of hepatic dextromethorphan O-demethylase activity 
selective for CYP2D6 in human organ donors 
Figure 2. Hepatic CYP2D6 activity (dextromethorphan O-demethylase) in subjects carrying 
various CYP2D6 genotypes 
 acceptable prediction from genotype,  underestimated phenotype from 
genotype,  overestimated phenotype from genotype,  chronic alcohol 
consumption,  subjects under CYP2D6 substrate drug therapy,  subjects under 
Augmentin therapy 
nf non-functional allele, red reduced-function allele  
 


